A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Trial details
- Registry ID
- NCT04576156
- Drugs studied
- Best Available Therapy (BAT), Imetelstat